Supplements

Tirzepatide improves patient-reported outcomes and objective assessments in adults with moderate-to-severe OSA and obesity, with greater improvements in those with worse baseline fatigue, sleepiness, or sleep quality.

In two 52-week randomized placebo-controlled trials (SURMOUNT-OSA), tirzepatide (10/15 mg) led to greater improvements in patient-reported outcomes (e.g., fatigue, sleepiness, sleep quality) and objective measures (AHI, weight, OSA remission) compared to placebo. Participants with worse baseline symptoms showed larger improvements on related PROMs, while objective improvements were similar across severity subgroups.

Last updated: Jul 10, 2026•1 RCTs•📖 Read as article →

Evidence Score

Evidence Score44/100
Human RCT★★☆☆☆
Meta-analysis☆☆☆☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses.

observational

Kanu C, Shinde S, Falcon B, Bednarik J, Xie CC, Trice K, Weaver T · Sleep (2026)

Participants: N/A
Duration: 52 weeks
Intervention: Tirzepatide 10 mg or 15 mg weekly
Outcome: Patient-reported outcomes (FOSQ Activity Level, SF-36v2 Vitality, SF-36v2 General Health, PROMIS Sleep-Related Impairment, PROMIS Sleep Disturbance) and objective assessments (AHI, SASHB, weight, OSA remission)
Effect Size: N/A (LS mean differences reported, e.g., FOSQ Activity Level: 0.33 vs 0.05; SF-36v2 Vitality: 8.5 vs 1.0; PROMIS Sleep-Related Impairment: -7.1 vs -1.6)
Population: Adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity, either not using PAP (Study 1) or using PAP (Study 2)

Result:

PubMed: 42412744DOI: 10.1093/sleep/zsag184

Mechanism Graph

Tirzepatide activates GIP and GLP-1 receptors
↓
Reduces appetite and promotes weight loss
↓
Weight loss reduces upper airway collapsibility and improves OSA severity
↓
Result: Improved patient-reported outcomes and objective OSA measures

Limitations

  • ⚠Post-hoc analyses are exploratory and not pre-specified, increasing risk of bias
  • ⚠Subgroup definitions based on self-reported baseline severity may be subjective and not validated

Frequently Asked Questions

What is tirzepatide?▼

Tirzepatide is a dual GIP and GLP-1 receptor agonist used for weight management and type 2 diabetes, and in this study, it was tested for obstructive sleep apnea.

How much did tirzepatide improve sleep-related outcomes?▼

Improvements varied by subgroup; for example, in fatigued participants, the SF-36v2 Vitality score improved by 8.5 points more than placebo, and in sleepy participants, PROMIS Sleep-Related Impairment improved by 7.1 points more than placebo.

Did tirzepatide work for all participants regardless of baseline severity?▼

Objective improvements (e.g., AHI reduction, weight loss) were similar across all severity subgroups, but patient-reported improvements were larger in those with worse baseline fatigue, sleepiness, or sleep quality.

What were the study durations?▼

Both studies lasted 52 weeks.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Kanu C, Shinde S, Falcon B, Bednarik J, Xie CC, Trice K, Weaver T. "Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: Post-hoc analyses.." Sleep, 2026. PMID: 42412744 DOI: 10.1093/sleep/zsag184
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.